The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Compliance concerns may be driven largely by the desire to say out of the regulatory spotlight, but it’s also a business strategy, a panel of experts told an audience during this week’s MassDevice.com Big 100 West event in Orange County, Calif.
Second Sight Medical’s Argus II "bionic eye" is likely the most talked-about medical device of 2013.
The retinal prosthesis, approved by the FDA last summer, isn’t slated to hit the market until 2014, but the buzz around the device is already at a fever pitch.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MassDevice held its 2nd annual Big 100 Roundtable East event in Waltham, Mass., July 10. A group of nearly 250 med-tech executives and stakeholders gathered for an evening of networking, insight into medical device marketing and intimate interviews with Michael Mahoney (incoming CEO of Boston Scientific), Abiomed CEO Michael Minogue and GI Dynamics CEO Stuart Randle.
Incoming Boston Scientific (NYSE:BSX) CEO Mike Mahoney is nothing if not optimistic about his upcoming tenure at the helm of the med-tech giant.
MassDevice.com is proud to announce an exceptional lineup of medical device leaders for the MassDevice Big 100 Regional Roundtable East on July 10, 2012, in Waltham, Mass.
The Big 100 Roundtable is a conversation among leaders – an unforgettable exchange of insight, ideas and contacts with the most prominent pioneers in our field.
Once again, MassDevice is combing the medical device industry to find the most innovative CEOs in the game – and we need your help to do it.
If the good people of Orange County felt a gale force wind a few weeks back, it may have been a sigh of relief coming from the Irvine, Calif. headquarters of Edwards Lifesciences Corp. (NYSE:EW) after the FDA finally gave a much-anticipated green light to the company’s Sapien transcatheter aortic valve.
Edwards had been hanging fire since July, when an FDA advisory panel recommended that the federal watchdog agency approve the device.
Joe Kiani is part of a pretty exclusive club. The founder, CEO and chairman of Masimo Corp. (NDSQ:MASI) built the company up from a start in his garage to a publicly traded company with more than 2,000 employees.
